Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment.
Hot flushes are the commonest symptom induced by gonadotropin-releasing hormone agonists (GnRHa). We performed an open observational trial to evaluate the efficacy of veralipride, an antidopaminergic drug, in reducing hot flushes in 25 premenopausal women treated with a GnRHa for endometriosis (8 subjects) or menorrhagia (17 subjects). The patients received goserelin depot for 6 months and veralipride was added for the third month. Hot flushes, severe in all women at 2 months, improved in both frequency and intensity in 92% of the subjects during veralipride administration. The benefit obtained persisted until the end of the GnRHa treatment.
Vercellini
P
P
L. Mangiagalli Department of Obstetrics and Gynecology, University of Milano School of Medicine, Italy.
Vendola
N
N
Colombo
A
A
Passadore
C
C
Trespidi
L
L
Crosignani
P G
PG
D000328:Adult; D004359:Drug Therapy, Combination; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy*; D004958:Estradiol / Q000097:blood; D005260:Female; D005483:Flushing / Q000139:chemically induced / Q000145:classification / Q000188:drug therapy*; D005640:Follicle Stimulating Hormone / Q000097:blood; D017273:Goserelin / Q000009:adverse effects*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008595:Menorrhagia / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D013469:Sulpiride / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D017273:Goserelin; D004958:Estradiol; D013469:Sulpiride; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C027429:veralipride